Featured Content
Opinion: Understanding the FDA's Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
"People have shown that the variant-identification quality of WGS is superior to WES," said Dr Gerstein.
Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
Patient-reported outcomes, or PROs, are going to play a larger role in FDA cancer drug approvals, according to an expert in the field.
Reducing the Reliance on Opioids for Cancer Pain: Is the Switch to Cannabis a Viable Option?
Articles discussing the use of cannabis as a substitute for opioids highlight the limitations of the existing scientific evidence in the field.More Features>>>
Endocrine Cancer News
Molecular Testing May Prevent Unnecessary Treatment of Suspicious for Malignancy Thyroid Nodules
October 05, 2018
MEK1/2 Inhibitor After RAI Fails to Improve Outcomes in High-Risk Nonmetastatic Thyroid Cancer
October 04, 2018
Endocrine Cancer Resources
More Information
Opioid Use and Cancer
February 22, 2019
This fact sheet discusses the use of opioids to control cancer pain and the risks of substance use disorder.
Clinical Applications of Liquid Biopsies in Cancer
February 15, 2019
This fact sheet describes liquid biopsies and their uses in oncology.
A Ketogenic Diet as an Adjunct to Cancer Treatment
February 08, 2019
The rationale for how keto could influence cancer is based on the established differences in glucose metabolism between cancer cells and normal cells.
Curcumin and Cancer
January 25, 2019
This fact sheet examines the data that suggest that curcumin has anticancer properties.
Fermented Dairy and Cancer
January 18, 2019
This fact sheet describes the potential relationship between fermented dairy intake and cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk